← ANALYST RATINGS · TIPRANKS
Verastem (VSTM): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $17.40, the highest $24.00, the lowest $12.00. The average is +101.2% from the last price of $8.65.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $13.00 → $14.00+7.7% | Buy | +61.8% | Reiterated | 16.10.26on TipRanks 07:35 | −5.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| Matthew Venezia★★★★★★★★★★#10510 · hits 33% · avg −7.8% | Alliance Global Partners | $18.00 → $22.00+22.2% | Buy | +154.3% | Reiterated | 15.10.26on TipRanks 08:45 | +19.4%next day −5.2% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $14.00 → $19.00+35.7% | Buy | +119.7% | Assigned | 15.10.26on TipRanks 07:36 | +19.4%next day −5.2% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $18.00 | Buy | +108.1% | Reiterated | 15.10.26on TipRanks 07:14 | +19.4%next day −5.2% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $24.00 | Buy | +177.5% | Reiterated | 14.10.26on TipRanks Oct 15 06:10 | +4.6%next day +19.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.50 → $7.50−11.8% | Hold | −13.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.50 → $7.50−11.8% | Hold | −13.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.50 → $7.50−11.8% | Hold | −13.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.50 → $7.50−11.8% | Hold | −13.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.00 → $8.00−11.1% | Hold | −7.5% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.50 → $7.50−11.8% | Hold | −13.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.50 → $9.00+5.9% | Hold | +4.0% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.50 → $8.00−5.9% | Hold | −7.5% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.50 → $8.00−5.9% | Hold | −7.5% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $14.00 | Buy | +61.8% | Reiterated | 08.10.26on TipRanks 21:45 | +2.7%next day −1.5% · 5 days +5.2% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $18.00 | Buy | +108.1% | Reiterated | 08.10.26on TipRanks 06:55 | −1.5%next day +2.7% · 5 days +14.1% | ↗ |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $18.00 | Buy | +108.1% | Reiterated | 05.10.26on TipRanks 09:10 | +3.2%next day −3.7% · 5 days +2.7% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $18.00 | Buy | +108.1% | Reiterated | 05.10.26on TipRanks 06:55 | +3.2%next day −3.7% · 5 days +2.7% | ↗ |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $7.50−6.2% | Hold | −13.3% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.50 → $8.00−5.9% | Hold | −7.5% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.50−6.2% | Hold | −13.3% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $8.50+6.2% | Hold | −1.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $8.00+6.7% | Hold | −7.5% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 | Hold | −7.5% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 | Hold | −7.5% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 | Hold | −7.5% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 | Hold | −13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 | Hold | −7.5% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 | Hold | −13.3% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $18.00 | Buy | +108.1% | Reiterated | 21.09.26on TipRanks 13:55 | +5.8%next day +4.8% · 5 days −1.7% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | — | Buy | — | Initiated | 17.09.26on TipRanks 07:25 | +2.0%next day −1.6% · 5 days +2.5% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $14.00 | Buy | +61.8% | Reiterated | 16.09.26on TipRanks Sep 17 21:45 | +0.2%next day +2.0% · 5 days +9.7% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $14.00 → $13.00−7.1% | Buy | +50.3% | Reiterated | 10.08.26on TipRanks 13:05 | +0.8%next day +4.1% · 5 days +5.8% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $14.00 → $12.00−14.3% | Buy | +38.7% | Reiterated | 06.08.26on TipRanks Aug 7 07:40 | +0.8%next day +13.4% · 5 days +11.6% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $18.00 | Buy | +108.1% | Reiterated | 06.08.26on TipRanks Aug 7 07:10 | +0.8%next day +13.4% · 5 days +11.6% | ↗ |
| James Molloy★★★★★★★★★★#12352 · hits 25% · avg −19.8% | Alliance Global Partners | $18.00 | Buy | +108.1% | Reiterated | 24.06.26on TipRanks 07:30 | −8.5%next day −10.5% · 5 days +4.8% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $15.00 → $8.00−46.7% | Buy | −7.5% | Reiterated | 23.06.26on TipRanks 08:40 | +0.5%next day −8.5% · 5 days −11.1% | ↗ |
| Unknown Analyst | B. Riley Securities | $16.00 | Buy | +85.0% | Initiated | 22.05.26on TipRanks May 23 23:05 | −1.1%next day +2.2% · 5 days −2.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Verastem
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.00 at a price of $8.05 (+86.3%); now: $18.17 at $8.65 (+110.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 19 | 16 | 14 | 9 | 16 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.47 (from $-0.60 to $-0.37). Last quarter: $-0.35.
Sales
Next quarter’s sales estimate — $27M (from $24M to $31M). Last quarter: $40M.
Best top-analyst consensus in the sector · Healthcare
About Verastem
- CEO: Daniel W. Paterson
- Employees: 102
- 117 Kendrick Street, Needham, MA, 02494, US
- www.verastem.com
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 68 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗